Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: is there a standard of care?
Head and neck cancer, comprising cancers of the oral cavity, larynx, nasopharynx, salivary gland, sinonasal cavity, oropharynx, and hypopharynx, is the 7th most common cancer worldwide [1]. Each year,>930,000 new cases of head and neck cancer are diagnosed, and nearly 470,000 people die from this disease [1]. This includes approximately 66,000 cases and 15,000 deaths in the United States, 153,000 cases and 69,000 deaths in Europe, and 24,000 cases and 8,000 deaths in Japan [2,3]. The majority of head and neck cancers ( ∼90%) are squamous cell carcinomas [4], and most patients (∼60%) are diagnosed with LA SCCHN [5]. (So...
Source: Cancer Treatment Reviews - June 14, 2023 Category: Cancer & Oncology Authors: Robert I. Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y. Lee Tags: Anti-tumour Treatment Source Type: research
The Evolution of Immune Checkpoint Inhibitor Combinations in Advanced Hepatocellular Carcinoma – A Systematic Review
Primary liver cancer is one of the most frequent causes of malignancy-related death globally, resulting in over 830,000 estimated deaths in 2020 [1]. It represents a continuously increasing health threat, with a 43% increase in deaths from this disease from 2000 to 2016 in the United States [2]. Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer, accounting for 75-85% of cases [3,4] and is unique in that it occurs largely in a background of chronic liver disease [5]. HCC is therefore associated with well-characterized risk factors including hepatitis B/C virus (HBV/HCV) infection, alcohol, diabetes, a...
Source: Cancer Treatment Reviews - May 27, 2023 Category: Cancer & Oncology Authors: Brandon M Meyers, Jennifer J Knox, David M Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C Tam, Howard J Lim Tags: Anti-tumour Treatment Source Type: research
Clinical trial designs for evaluating and exploiting cancer evolution
Cancer is a genetic disease[1], with cells constantly turning over and acquiring changes in gene function over time. It can also be defined as a disease of evolution, governed by environmental selection of phenotypic features. Interestingly, while some of the genetic changes can be transient, such as modification in gene expression or post-translational function of encoded proteins, a proportion of genetic changes are irreversible and inherited by daughter cells leading to tumour evolution.[2 –6] Some of these genetic changes are deleterious and result in cell death, others are neutral, and a few are advantageous and dri...
Source: Cancer Treatment Reviews - May 24, 2023 Category: Cancer & Oncology Authors: Alvaro H Ingles Garces, Nuria Porta, Trevor A Graham, Udai Banerji Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 21, 2023 Category: Cancer & Oncology Source Type: research
TROP-2 directed Antibody-Drug Conjugates (ADCs): the revolution of smart drug delivery in advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death in both male and female worldwide, accounting for nearly 20% of all cancer deaths in Europe. [1,2] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 19, 2023 Category: Cancer & Oncology Authors: Parisi Claudia, Mahjoubi Linda, Gazzah Anas, Barlesi Fabrice Tags: Systematic or Meta-analysis Studies Source Type: research
Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: a systematic review
Lung cancer is the leading cause of cancer death worldwide with an estimated 1.8 million deaths per year [1], mainly represented by non-small cell lung cancers (NSCLC). Approximately one third of patients is diagnosed with locally advanced disease (LA) [2]. Many of these patients have unresectable disease or are medically inoperable. The definition of unresectable stage III NSCLC varies and may include technically resectable disease [3]. There is consensus that the overall survival (OS) of most patients is similar whether treated locally with surgery or radiotherapy. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 15, 2023 Category: Cancer & Oncology Authors: Beno ît ALLIGNET, Dirk DE RUYSSCHER, Isabelle MARTEL-LAFAY, Waisse WAISSI Tags: Systematic or Meta-analysis Studies Source Type: research
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis
Epithelial ovarian cancer includes different histotypes: high-grade serous, low-grade serous, mucinous, clear cell, and endometrioid. The aim of ovarian cancer treatment is complete remission through surgery and the administration of chemotherapy (CT), usually carboplatin in combination with paclitaxel +/- bevacizumab). First-line treatment for advanced ovarian cancer can be followed by relapse (occurring in approximately 70% of patients within 3 years of first-line treatment)1 and is characterized by a dismal prognosis for stage III (5-year survival rate:20%) and stage IV (5-year survival rate:5%)2. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 11, 2023 Category: Cancer & Oncology Authors: Fausto Petrelli, Carmen Rea, Cinzia Solinas, Antonio Ghidini, Karen Borgonovo, Andrea Celotti, Antonella Villa, Andrea Luciani, Domenica Lorusso Tags: Systematic or Meta-analysis Studies Source Type: research
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511]
The authors regret that one of the author ’s names and their affiliation details were incorrect in the above-mentioned article. The correct author name is ‘Michelino De Laurentiis’ and his affiliation updated as above. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 5, 2023 Category: Cancer & Oncology Authors: F. Miglietta, A. Fabi, D. Generali, M.V. Dieci, G. Arpino, G. Bianchini, S. Cinieri, P.F. Conte, G. Curigliano, Michelino De Laurentiis, L. Del Mastro, S. De Placido, A. Gennari, F. Puglisi, A. Zambelli, F. Perrone, V. Guarneri Source Type: research
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Although metastatic breast cancer (BC) is unlikely to be cured, there have been meaningful improvements in survival due to the increasing availability of more effective systemic therapies, including both endocrine backbones as well as targeted agents. Hormone receptor positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) BC accounts for almost two thirds of BC diagnoses, and inhibiting estrogen receptor (ER) signaling with endocrine therapies (ETs) still represents the mainstay of the treatment for this subtype, in both early and advanced settings [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 27, 2023 Category: Cancer & Oncology Authors: Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Hamilton, Rinath Jeselsohn, Komal Jhaveri, Giuseppe Curigliano, Carmen Criscitiello Tags: New Drugs Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 26, 2023 Category: Cancer & Oncology Source Type: research
Proteolysis Targeting Chimeras in Non-Small Cell Lung Cancer
Lung cancer is the most common cause of cancer-related deaths globally. [1] The majority of non-small cell lung cancer ’s (NSCLC) are diagnosed in advanced stages. [2] Historically, the prognosis of NSCLC has been very poor; However, the development of targeted therapies has greatly improved survival. Targeted therapies are more efficacious compared to chemotherapy and have fewer side effects. As a result, the ini tial evaluation of most cancers involves collection of molecular and genetic data. The use of targeted therapies has become prominent in NSCLC since the advent of the first epidermal growth factor (EGFR) tyrosi...
Source: Cancer Treatment Reviews - April 26, 2023 Category: Cancer & Oncology Authors: Garo Hagopian, Christopher Grant, Misako Nagasaka Tags: Anti-tumour Treatment Source Type: research
Function and targeting of MALT1 paracaspase in cancer
Human MALT1 (mucosa associated lymphoid tissue protein 1) was originally identified from the translocation breakpoint t(11;18)(q21;q21), which is found predominantly in late-stage MALT lymphomas [1,2]. Sequence comparisons of MALT1 indicated an enzymatic function of the paracaspase domain that comprises a caspase-like fold as found in caspases [3]. Thus, MALT1 (also termed PCASP1) is the founding and only human member of the paracaspase family of cysteine proteases [4], raising considerable interest in MALT1 as a drug target. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 26, 2023 Category: Cancer & Oncology Authors: Thomas J. O'Neill, Marie J. Tofaute, Daniel Krappmann Tags: Anti-tumour Treatment Source Type: research
Uncertainties and Controversies in Axillary Management of Patients with Breast Cancer
Management of the axilla in patients with early breast cancer (BC) has undergone major changes in the last few years due to multimodality approaches and the declining status of axillary surgery as a staging procedure. This process of surgical de-escalation began when sentinel lymph node (SLN) biopsy replaced axillary lymph node dissection (ALND) as standard of care in patients with node-negative breast cancer.[1] The progressive reduction of surgical intervention continues following publication of practice changing trials, such as ACOSOG Z0011, IBCSG 23-01 and EORTC AMAROS. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 22, 2023 Category: Cancer & Oncology Authors: Walter P Weber, Oreste Davide Gentilini, Monica Morrow, Giacomo Montagna, Jana de Boniface, Florian Fitzal, Lynda Wyld, Isabel T. Rubio, Zoltan Matrai, Tari A. King, Ramon Saccilotto, Viviana Galimberti, Nadia Maggi, Mariacarla Andreozzi, Virgilio Sacchin Tags: Controversy Source Type: research
Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists
Neuroendocrine neoplasms (NEN) are a variegated family of malignancies originating from the diffuse neuroendocrine system. They are mainly distinguished into “well differentiated” (WD) and “poorly differentiated” (PD) and are commonly named neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), respectively. This derives from the gastroenteropancreatic (GEP) WHO classification terminology that categorized these neoplasms in WD NET grade s 1, 2 and 3 or PD NEC [1]. Specifically, a Ki-67>20% defines the high-grade category, including NET G3 and NEC [2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 17, 2023 Category: Cancer & Oncology Authors: La Salvia A., Modica R., Rossi R.E., Spada F., Rinzivillo M., Panzuto F., Faggiano A., Cinieri S., Fazio N. Tags: Anti-tumour Treatment Source Type: research
Immediate hypersensitivity reactions to antineoplastic agents – a practical guide for the oncologist
Immediate hypersensitivity reactions (IHRs) to antineoplastic agents can have potentially life-threatening consequences [1]. It is therefore crucial for an oncologist to be capable to promptly recognize signs and symptoms, correctly diagnose, adequately treat, and prevent recurrence of these types of reactions. IHRs comprise all reactions that occur up to six hours, though typically within 1 hour or even minutes from the first dose of a new treatment course, and that cannot be explained by the known toxicity profile of a drug [2,3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 12, 2023 Category: Cancer & Oncology Authors: Sofie Seghers, Laure-Anne Teuwen, Michiel Beyens, Dennis De Blick, Vito Sabato, Didier G. Ebo, Hans Prenen Source Type: research
